Sun Pharmaceutical Industries, Inc. secured FDA approval for its oral generic Dapagliflozin and Metformin Hydrochloride tablets, positioning the company to expand its competitive presence in the diabetes management market. This regulatory milestone is expected to drive incremental sales revenue while intensifying competition and potential phasing-out effects for branded alternatives.